Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $135
Benzinga Newsdesk 21 hours ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $130 to $135.
Guggenheim analyst Yatin Suneja maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $130 to $135.